COPYRIGHT MEDINEWS (DIABETES) LIMITED
|
|
- Poppy Newton
- 7 years ago
- Views:
Transcription
1 Owens p-66 8/5/07 4:19 pm Page 1 Insulin glulisine the potential for improved glycaemic control DAVID R OWENS Abstract Tight glycaemic control is essential to reduce the risk of developing the micro- and macrovascular complications of diabetes. Plasma levels of glycosylated haemoglobin (HbA 1C ) are a marker for long-term glycaemia; controlling these levels within tight limits forms the cornerstone of long-term diabetes management. As a result of evidence from key clinical trials in type 1 and type 2 diabetes, HbA 1C targets ranging from < 6.5 to < 7.5% have been set by various authorities. To achieve these targets, insulin regimens need to reflect normal physiological insulin release. Several rapid- and long-acting insulin analogues have been developed to mimic aspects of insulin secretion. Insulin glulisine is a genetically engineered insulin which has a rapid onset and short lived action, allowing it to closely mimic prandial release of insulin. In addition to the structural change in the insulin molecule, the absence of excess zinc and the addition of polysorbate 20 as a surfactant facilitates its disassociation in the subcutaneous tissue and inhibits its aggregation when used in subcutaneous insulin delivery systems due to improved physical stability. Br J Diabetes Vasc Dis 2007;7:-66 Key words: insulin glulisine, pharmacokinetics, pharmacodynamics, type 1 diabetes, type 2 diabetes. Correspondence to: Professor David R Owens Diabetes Research Unit, 1st Floor Academic Centre, Llandough Hospital Penlan Road, Penarth, CF64 2XX, UK. Tel: +44 (0) ; Fax: +44 (0) owensdr@cardiff.ac.uk David R Owens Introduction Evidence that tight glycaemic control reduces the risk of microand macrovascular complications of diabetes continues to accrue. It is well established that tight glycaemic control significantly lowers the risk of microvascular complications in both type 1 and type 2 diabetes. 1,2 The DCCT/EDIC study demonstrates a significant association between tight glycaemic control and a reduction in the risk of cardiovascular events in type 1 diabetes. 3 Over the 10 years of the complementary trial in type 2 diabetes, the UKPDS, HbA 1C was 7.0% in a group intensively treated with sulphonylureas or insulin versus 7.9% in a conventionally nonpharmacological treated group. This improvement in glycaemic control was associated with a 16% reduction in the risk of MI, (p=0.052). 1 UKPDS has also shown that individuals who suffered a fatal MI had a higher HbA 1C than those who suffered non-fatal MI, with a 17% reduction in the odds of suffering MI per 1% reduction in HbA 1C (p=0.014). 4 Several UK initiatives have been published in an attempt to incorporate these important research findings into everyday clinical practice, including the NSF for Diabetes, the NICE guidelines and the GMS contract policy initiative. 5-7 These strategies are important as the number of patients who do not achieve adequate control of glycaemia and have associated vascular risk factors remains unacceptably high. This situation has led to an increased focus on the development of effective insulin regimens to optimise control of glycaemia and to reduce vascular risk. 8,9 The quest for long-term maintenance of optimal glycaemia has also led to the increasing recognition of the need for timely introduction of insulin therapy in those with type 2 diabetes. 9 Since 1996, optimal glycaemic control through the use of more effective insulin regimens has been brought a step closer with the introduction of long-acting insulin analogues, such as insulin glargine (in 2000) and insulin detemir (in 2004), and rapid acting insulin analogues, such as insulin lispro (in 1996), aspart (in 1999) and, most recently, insulin glulisine (at the end of 2004). These rapid-acting insulin analogues were genetically engineered to more closely mimic physiological insulin delivery in response to a nutrient challenge. THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
2 Owens p-66 8/5/07 4:19 pm Page 2 Abbreviations BMI body mass index CC creatinine clearance CSII continuous subcutaneous insulin infusion GMS General Medical Service HbA 1C haemoglobin A 1C NICE National Institute for Clinical Excellence NPH Neutral Protamine Hagedorn NSF National Service Framework MI myocardial infarction RHI regular human insulin SMBG self monitoring of blood glucose Limitations of regular human insulin Glycaemic control Fasting and mealtime (prandial) glycaemia contribute to overall glycaemic control, and these must be addressed to achieve effective diabetes management. 15 Postprandial glucose is a major contributor to total glycaemic control where HbA 1C levels are below approximately 7%, whilst fasting blood glucose is the major contributor where HbA 1C is higher. 15 The DECODE study reported increased cardiovascular risk associated with hyperglycaemia after a glucose challenge. 16 The evidence for the molecular mechanisms by which this postprandial hyperglycaemia accelerates the atherosclerotic process is accumulating. 17 Until the development of the insulin analogues in the mid 1990s, the most effective method of achieving good glycaemic control was the use of a combination of short-acting formulations of RHI and longer-acting isophane or lente insulin preparations. However, RHI is not ideal for the control of prandial glycaemia; because of its conjugation to zinc which stabilises the hexameter and retards its dissociation, thereby slowing its absorption from the subcutaneous tissue. It has an onset activity of about 30 minutes following subcutaneous injection, with the concentration in the blood reaching a plateau at 2 3 hours followed by a slow fall to baseline over the subsequent 6 10 hours. 18 Acronyms DCCT/EDIC DECODE HPS UKPDS Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe study Heart Protection Study United Kingdom Prospective Diabetes Study This article highlights certain molecular and clinical attributes that mark insulin analogues as potentially important advances in the evolution of effective prandial insulin therapy and focuses on insulin glulisine. Insulin glulisine differs from human insulin by the replacement in the B-chain of the amino acid asparagine with lysine at position three and lysine with glutamic acid at position 29. These changes reduce the tendency for the insulin glulisine molecule to form dimers by inducing slight steric and electrostatic repulsion between two insulin monomers, which also incresases the rate of dissociation in the subcutaneous tissue and consequently its absorption leading to a more rapid onset of action compared to RHI Insulin glulisine has been shown in obese normal subjects to have advantages over insulin lispro and RHI in terms of absorption at different levels of BMI and subcutaneous fat thickness. 13 This trend has also been seen in a small study involving subjects with type 2 diabetes, but the difference only achieved a small impact on the postprandial glucose profiles in these subjects. 14 Adverse events and compliance Intensive insulin therapy with conventional insulin regimens is associated with weight gain and risk of hypoglycaemia. The DCCT showed that intensifying conventional insulin treatment reduced the risk of diabetic complications. 2 However, there were 62 hypoglycaemic episodes per 100 patient-years in the intensive treatment arm of the DCCT, compared with 19 such episodes per 100 patient-years in the conventional treatment group. 2 Patients in the intensive treatment arm also gained 4.6 kg more in weight than those in the comparator group. Administration of RHI up to half an hour before meals may also be a barrier to compliance. Patients frequently ignore this recommendation in favour of injecting at a more convenient time, 19 which leads to suboptimal glycaemic control and an increased risk of interprandial and/or nocturnal hypoglycaemia. 20 Improving the pharmacodynamics of insulin through genetic engineering An ideal insulin regimen would achieve tight glycaemic control and avoid hypoglycaemia whilst allowing mealtime flexibility and convenience of administration. The advent of recombinant DNA technology has facilitated the availability and production of rapid-acting (figure 1) and longer-acting and peakless basal insulin analogues. 18,21 Such molecular modifications are taking us a step closer to reaching an ideal regimen. Further modification in the zinc content and additives used in the pharmaceutical preparations can further influence the pharmacokinetics, pharmacodynamics and stability of the insulin analogues. With rapid-acting insulin analogues, changes in the amino acid structure promote charge repulsion, which reduces the tendency of the protein to remain aggregated in the hexameric and dimeric state thus increasing the rate of absorption from the subcutis. 10 (figure 1) Pharmacokinetics and pharmacodynamics of insulin glulisine versus RHI In a phase I, cross-over study in 16 healthy individuals without diabetes, insulin glulisine efficacy was equivalent to RHI. Using the euglycaemic clamp method 23 at steady-state ( minutes after the start of 0.08 mu kg -1 /min -1 insulin infusion), VOLUME 7 ISSUE 2. MARCH/APRIL
3 Owens p-66 8/5/07 4:19 pm Page 3 Figure 1. Amino acid structure of the three rapid-acting insulin analogues A Chain Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn Insulin lispro B Chain Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Lys Pro Thr A Chain B Chain A Chain B Chain Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn insulin glulisine and RHI achieved similar glucose utilisation (GIR-AUC SS 214 mg/kg -1 and 209 mg/kg -1, respectively), glucose infusion rates (GIR SS 1050 mg/kg -1 and 995 mg/kg -1, respectively) and total glucose disposal rates (GIR-AUC 0 clamp end 1050 mg/kg -1 and 995 mg/kg -1, respectively). 23 The rate of absorption of insulin glulisine is equivalent to the rapid-acting insulin analogue, insulin lispro, and almost twice as fast as RHI (T max 56, 50 and 99 minutes, respectively). 24 Additionally, both rapid-acting analogues had a lower mean residence time and duration of action than RHI. Insulin glulisine can be used in CSII systems owing to the use of polysorbate 20 as an excipient. This improves the stability of insulin exposed to thermal and mechanical stress, which otherwise would lead to catheter occlusion due to autocatalytic fibrie formulation with insulin precipitation. 25 A 12-week, randomised, open-label study involving 59 patients with type 1 diabetes, found no significant differences in efficacy or safety Insulin aspart Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Asp Lys Thr Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn Insulin glulisine Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr Insulin lispro is so named because of the substitution of amino acids lysine (lys) and proline (pro) at positions B28 and B29 in place of proline and lysine, respectively, in normal human insulin. Insulin aspart, meanwhile, has aspartate at position B28 instead of proline. In the case of glulisine, the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. 22 These modifications result in a faster rate of absorption and onset of action and with a shorter duration of action compared with RHI between insulin glulisine and insulin aspart when used in CSII systems. The rate of catheter occlusions in the insulin glulisine and insulin aspart groups was and occlusions/month, respectively (p=0.06). One patient in the insulin aspart group suffered unexplained hyperglycaemia associated with catheter occlusion while unexplained hyperglycaemia in the presence or absence of pump occlusions occurred in 6 patients (20.7%) in the insulin glulisine group compared with 12 patients (40.0%) in the insulin aspart group. It should be noted, however, that catheter occlusions are not a commonlyreported problem and caution should be taken before altering clinical practice based on the evidence from a single study. Infusion site reactions occurred in three patients in the insulin glulisine group and in four patients receiving insulin aspart. End point HbA 1C levels were similar in the insulin glulisine and insulin aspart treated groups (6.98% and 7.18%, respectively) THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
4 Owens p-66 8/5/07 4:19 pm Page 4 Further phase I studies have shown that the absorption, pharmacokinetics and glucodynamics of insulin glulisine are largely unaffected by the site of injection 27 and its pharmacokinetics are consistent across a range of populations. 28 It is known that obesity adversely affects the absorption of RHI and the consistency of the pharmacokinetic profile of rapid-acting insulin analogues in obese versus non-obese individuals will potentially have particular importance for the control of postprandial hyperglycaemia in patients with type 2 diabetes. In a randomised study of 18 obese individuals without diabetes (mean BMI 34.7 kg/m 2 ), insulin glulisine and insulin lispro had a more marked rapid time action profile compared to RHI. Compared to RHI and insulin lispro, the pharmacokinetics and pharmacodynamics of insulin glulisine were less influenced by subcutaneous adiposity and not significantly related to BMI. 13 The relationship between BMI and insulin aspart was investigated in a separate study of obese individuals with type 1 diabetes. 29 Increasing obesity was associated with a decreased apparent clearance rate per kg body weight, increased half-life and increased insulin area under the curve, but these results were not considered to be clinically significant by the authors as the changes observed were less than the individual variations for these parameters. The pharmacokinetics of insulin glulisine and RHI were also compared in a single-dose study involving ten children (aged 5 11 years) and ten adolescents (aged years) with type 1 diabetes. 30 In this randomised, cross-over study, mean residence time for insulin glulisine was distinctly shorter at 88 minutes compared with 137 minutes for RHI (p<0.05), and the insulin C max and AUC 0 2h were 76% and 75% higher for insulin glulisine compared with RHI (p<0.05 for both observations). Therefore, the pharmacokinetic differences between insulin glulisine and RHI observed in children and adolescents mirrored those observed in adults. A single-dose study examined the pharmacokinetics of insulin glulisine in non-diabetic individuals (mean age 56 years; mean BMI 26 kg/m2) with normal renal function (CC > 80 ml/min, n=8), moderately impaired renal function (CC ml/min, n=8) or severely impaired renal function (CC < 30 ml/min, n=8). No apparent differences in the insulin glulisine concentration time profiles were observed for the three subgroups and there was no relationship between the estimated creatinine clearance and the rate of onset or duration of action. The authors concluded that dose adjustments for renal insufficiency, other than those required to compensate for any co-existing level of insulin resistance, would be unnecessary. 31 Any requirement to reduce the dose in individual subjects with end-stage renal disease will need to be based on clinical judgement. Table 1. Mean blood glucose measurements 33 patients with type 1 diabetes on basal (insulin glargine) bolus (insulin glulisine or RHI) regimens Pre-meal RHI Pre-meal Post-meal (30 45 min) (0 15 min) (0 15 min) insuline insulin glulisine glulisine 2-hour post-breakfast glucose levels (mmol/l) * 2-hour post-dinner glucose levels (mmol/l) ** Key: *p=0.0017, **p=0.0137, p= vs. pre-meal RHI Clinical efficacy of insulin glulisine versus RHI Insulin glulisine versus RHI in type 1 diabetes In addition to the differences in the pen injected devices between different insulins, which in itself may be an important aspect of patient acceptability of any treatment, the requirement to inject RHI 30 minutes before a meal places constraints on patients and limits mealtime flexibility. Rapid-acting insulin analogues provide a more convenient option for prandial glucose control, as demonstrated in studies of insulin glulisine versus RHI in patients with type 1 diabetes. 32 In a single-dose, four-arm, cross-over study, insulin glulisine was administered either immediately before or 15 minutes after a standard meal whereas RHI was administered either immediately or 30 minutes before the same standard meal. The study compared the relative abilities of these regimens to control postprandial blood glucose levels in 20 patients with type 1 diabetes. 32 The study results showed that insulin glulisine given pre-meal (0 15 minutes) provided more effective prandial glucose control than RHI, when administered 30 minutes before the meal (figure 2). A further trial of 8 patients with type 1 diabetes was undertaken, 33 in which all patients received once-daily insulin glargine and were randomised to one of three treatment groups: insulin glulisine 0 15 minutes before meals, insulin glulisine 0 15 minutes after meals or RHI minutes before meals. 33 Reductions in HbA 1c were similar for the postmeal insulin glulisine and pre-meal RHI groups (-0.11 and -0.13%, respectively), but were significantly greater in the premeal insulin glulisine group (-0.26%) vs. RHI (p=0.02) and vs. post-meal insulin gluisine (p=0.0006). Giving insulin gluisine post-meal achieved equivalent overall glycaemic control to RHI given before the meal. The pre-meal administration of insulin glulisine was more effective than post-meal insulin glulisine and RHI in reducing postprandial glycaemia (table 1). Post-meal insulin glulisine was associated with a mean 0.3 kg weight reduction compared to a mean 0.3 kg weight gain for pre-meal RHI (p=0.03). Results of the safety assessments, including the incidence of hypoglycaemia, were similar among the three groups. Importantly, these results support the hypothesis that rapidacting insulin analogues provide more mealtime flexibility. A VOLUME 7 ISSUE 2. MARCH/APRIL
5 Owens p-66 8/5/07 4:19 pm Page 5 Figure 2. Insulin glulisine (GLU given 0 2 minutes prior to the standard meal provides more effective glucose disposal than regular human insulin (RHI) 0 2 minutes prior to the test meal. Glulisine immediately pre-meal was equivalent to RHI given 30 minutes before the standard meal. Giving insulin glulisine 15 minutes after the meal was equally effective to pre-meal RHI GLU pre-meal vs. RHI 30 minutes pre-meal GLU pre-meal vs. RHI pre-meal GLU post-meal vs. RHI pre-meal Glucose (mg/dl) Key: GLU (pre) RHI (30 minutes) Time (hours) sub-analysis of this study also highlights the potential of rapidacting analogues to reduce insulin dose in patients with type 1 diabetes, when titrated to blood glucose targets and avoiding hypoglycaemia. 34 While 32.7% of those receiving pre-meal RHI were able to reduce their total daily insulin dose, a significantly greater proportion of those receiving insulin glulisine pre- and post-meal reduced their insulin dose by 46.1% and 46.6% respectively (p= vs. RHI and p= vs. RHI, respectively). The sub-analysis further illustrated the beneficial effects of insulin glulisine on weight gain over the 12-week study period: 37.6% in the RHI group, 32.2% in the pre-meal insulin glulisine group and 26.0% in the post-meal insulin glulisine group gained > 1 kg in body weight. The difference for post-meal insulin glulisine versus RHI reached statistical significance (p=0.0035). Glucose (mg/dl) GLU (pre) RHI (pre) Time (hours) indicates meal administration; GLU = glulisine; RHI = regular human insulin Glucose (mg/dl) GLU (post) RHI (pre) Time (hours) Insulin glulisine versus RHI in type 2 diabetes A similar study was undertaken in persons with type 2 diabetes to examine the safety and efficacy of insulin glulisine versus RHI. In this study, a basal bolus regimen was used in a multicentre, open-label, 26-week trial. 35 A total of 867 patients who were relatively well controlled (mean HbA 1C of 7.6%) with insulin alone or insulin plus oral antidiabetic therapy were randomised to receive treatment with either insulin glulisine plus NPH insulin or RHI plus NPH insulin. A greater reduction in HbA 1C from baseline was observed in the insulin glulisine group compared with the RHI treatment group (-0.46% vs %, p=0.0029). Subjects in this study conducted SMBG, recording seven data points at set times during the day. In contrast to baseline values, which were comparable for the two groups, the SMBG values were lower in persons receiving insulin glulisine than in those receiving RHI. The differences were statistically significantly different for blood glucose values reached two hours after breakfast and two hours after dinner (p<0.05). 35 As with studies in type 1 diabetes, the safety assessments showed no significant differences in the rates of adverse events between insulin glulisine and RHI, including injection site reactions (3.2% vs. 2.3% for insulin glulisine and RHI, respectively). 30 These results in patients with type 2 diabetes show the potential of preprandial insulin glulisine to provide equivalent or better overall glycaemic control to preprandial RHI when used to improve prandial glucose control, without causing additional weight gain or increasing the risk of hypoglycaemia. Insulin glulisine a step towards optimal glycaemic control Reducing the risk of vascular complications remains the primary focus of diabetes management. While the contribution of hyperglycaemia to microvascular complications has long been established, its role in macrovascular complications is becoming increasingly apparent. The development of rapid-acting insulin analogues provides a significant step towards achieving optimal glycaemic control by providing improved prandial glucose control. Whilst the safety of insulin glulisine has been demonstrated in children and adolescents, 30 future longer-term studies of this 64 THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE
6 Owens p-66 8/5/07 4:19 pm Page 6 Key messages Tight glycaemic control can reduce vascular complications of diabetes. Optimal glycaemia requires effective treatment regimens which mirror physiological insulin release Insulin glulisine is a genetically engineered insulin with a rapid onset of action which closely mimics prandial insulin release. Its short duration of action reduces the risk of interprandial hypoglycaemia In type 2 diabetes insulin glulisine has been shown to improve HbA 1C levels compared with regular human insulin The pharmacokinetics and pharmacodynamics of insulin glulisine in contrast to regular human insulin are less influenced by BMI in non-diabetic patients. If these reflect the situation in obese people with diabetes, then this may indicate that effectiveness would be maintained in such individuals of insulin gluisine rapid-acting insulin analogue are needed to include studies in pregnant women, to determine the safety profile for both the mother and the unborn child. Further studies of the rapid-acting insulin analogues will also allow the evaluation of better control of postprandial hyperglycaemia on the atherosclerotic process. Insulin glulisine provides benefits including significantly more effective control of HbA 1C levels compared to RHI in a basal bolus regimen with NPH in persons with type 2 diabetes. Its rapid onset of action is maintained over a wide range of BMIs. The flexability to administer insulin glulisine pre- and post-meal provides added convienience. Further potential potential benefits includes limiting weight gain compareed to RHI for equivalent glycaemic control in persons with type 1 diabetes. Conclusion Insulin glulisine will provide healthcare professionals with an additional therapeutic option that may increase their ability to improve prandial glucose control and better meet national standards of diabetes care. This should lead to a reduction in the massive burden of vascular disease that is currently associated with diabetes. References 1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: The Diabetes Control and Complications (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353: Stevens RJ, Coleman RL, Adler AI et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. UKPDS 66. Diabetes Care 2004;27: Department of Health. National Service Framework for Diabetes: Delivery Strategy National Institute for Clinical Excellence. Management of type 2 diabetes: Management of blood glucose (inherited clinical guideline G) National Health Service Confederation and British Medical Association. The new GMS Contract. 2003; primary/primary-902.cfm. 8. Bohannon NJ. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgrad Med 2003;113:39-42,45-8, Barnett AH, Capaldi B, Davies-Lyons M et al. Expert opinion statement on the use of insulin therapy in patients with Type 2 diabetes in primary care. Practical Diabetes International 2003; 20: Brange J, Owens DR, Kang S et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13: Electronic Medicines Compendium. 2006; Becker RH. Insulin Glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther : Becker RH, Frick AD, Burger F et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005; 113: Luzio S, Dunseath G, Peter R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006; 49: Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26: DECODE Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26: Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164: Feher MD, Bailey CJ. Reclassifying insulins. Br J Diabetes Vasc Dis 2004;4: Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43: Betz JL. Fast-acting human insulin analogs: a promising innovation in diabetes care. Diabetes Educ 1995;21: Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358: Summary of Product Characteristics. emc.medicines.org.uk/ 23. Becker RH, Frick AD, Burger F et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005;113: Becker RHA, Frick AD, Wessels DH et al. Pharmacodynamics and pharmacokinetics of a new rapidly-acting insulin analog, insulin glulisine. Diabetes 2003;52(suppl 1)pA110(Abstract 471-P). 25. Brange J, Langkjoer L. Insulin structure and stability. Pharm Biotechnol 1993;5: Hanaire-Broutin H, Schumicki DM, Hoogma RPLM et al. Safety of insulin glulisine compared with insulin aspart administered by VOLUME 7 ISSUE 2. MARCH/APRIL
7 Owens p-66 8/5/07 4:19 pm Page 7 continuous subcutaneous insulin infusion (CSII). ADA Conference Frick A, Becker R, Wessels D et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites. Diabetes 2003;52(suppl 1)A118 (Abstract 511-P). 28. Frick A, Becker R. Predictable and consistent insulin glulisine pharmacokinetics in various populations - an across phase study analysis. Diabetes 2005;54(suppl 11):pA518(Abstract 2154). 29. Holmes G, Galitz L, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;: Danne T, Becker RH, Heise T et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28: Jaros M, Martinek R, Piechatzek R et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients. ADA Conference Nosek L, Becker R, Frick A et al. Prandial Blood Glucose Control with Pre- and Post-Meal Insulin Glulisine Versus Regular Human Insulin. Diabetes 2004;53(suppl 2):A139(Abstract 588-P). 33. Garg S, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in Type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005;11: Garg S, Chen Y, Souhami E. Reduction in insulin dose and body weight with pre- and post-meal insulin glulisine (GLU) versus regular human insulin (RHI) in patients with type 1 diabetes. Diabetes 2005;54(suppl 1):A144 (Abstract 581-P). 35. Dailey G, Rosenstock J, Moses R. Insulin glulisine provides improved glycaemic control in patients with type 2 diabetes. Diabetes Care 2004;27:
Insulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationManagement of Diabetes Mellitus with Insulin Lispro
Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management of Diabetes Mellitus with Insulin Lispro Masami
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationINSULIN REGIMENS in type 2 diabetes
A review of INSULIN and INSULIN REGIMENS in type 2 diabetes a Joshi P, PhD, FRCP,FRS Med, FICA Joshi S, MBChB, MSc(Pharm) Med(UL) Diabetes Care Centre, Louis Pasteur Medical Centre, Pretoria a Emeritus
More informationDesigner Insulins. History case 1. Follow up - case 1. Follow up - case 1. History - case 2. 24 hr glucose profile - case 1
History case 1 33 yr old male bank manager Designer Insulins Dr A Qureshi MB ChB (Edin), MD (Lon), CCT (Lon), FRCP (Lon) Consultant in Endocrinology, Diabetes and General Internal Medicine w w w. e n d
More informationEASD/ADA 2015 Highlights- insulin. Dr Jarl Hellman
EASD/ADA 2015 Highlights- insulin Dr Jarl Hellman Innehåll NPH Epidemiologi Nya insuliner Basinsulinets bäste vän exklusive hund och UKPDS? G.B Bolli Hypoglykemi - NPH Exogenous insulin and risk of all-cause
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationBasal Insulin Analogues Where are We Now?
232 Medicine Update 41 Basal Insulin Analogues Where are We Now? S CHANDRU, V MOHAN Insulin is a polypeptide secreted by the beta cells of pancreas and consists of 51 amino acids (AA). It has two polypeptide
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationRight Insulin Regimen
Focus on CME at l Université McGill University de Montréal What is the Right Insulin Regimen for my Patient? Jean-Pierre Hallé, MD, FRCPC, and Donald Breton, MD, FRCPC What can I do to improve my patient
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationIntroduction. original article
Diabetes, Obesity and Metabolism 13: 251 257, 2011. 2011 Blackwell Publishing Ltd Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationEfficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus
Clin Pediatr Endocrinol 2002; 11(2), 87-92 Copyright 2002 by The Japanese Society for Pediatric Endocrinology Original Efficacy and Safety of Insulin Aspart in Patients with Type 1 Diabetes Mellitus Toshikazu
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationINSULIN PRODUCTS. Jack DeRuiter
INSULIN PRODUCTS Jack DeRuiter The number and types of insulin preparations available in the United States is constantly changing, thus students should refer to recent drug resources for a current list
More informationAims To compare the effects on glycaemic control after using continuous subcutaneous insulin infusion (CSII) or insulin glargine.
DOI: 10.1111/j.1464-5491.2004.01444.x Optimization of basal insulin delivery in Type 1 diabetes: Oxford, DME Diabetic 0742-3071 Blackwell 21 Original UK Article article Medicine Publishing, of basal insulin
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationInsulin initiation in type 2 diabetes: Experience and insights
Insulin initiation in type 2 diabetes: Experience and insights Joan Everett A diagnosis of type 2 diabetes can be devastating for the individual and their family. Furthermore, many people with diabetes
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More information10 to 30 minutes ½ to 3 hours 3 to 5 hours. 30 60 minutes 1 to 5 hours 8 hours. 1 to 4 hours
Insulin Action There are several types of insulin. They are classified by how long they act: very fast, fast, slow and very slow acting. Each type of insulin has a certain time period in which it works.
More informationInsulin: A Powerful Weapon in the Diabetic Arsenal. Diana Cowell, PharmD PGY-1 Pharmacy Resident
Insulin: A Powerful Weapon in the Diabetic Arsenal Diana Cowell, PharmD PGY-1 Pharmacy Resident Objectives Identify the mechanism of action of insulin Describe the onset and duration for the various types
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationPrinciples on Insulin Treatments. Insulin & Type 2 Diabetes. Natural History of Type 2 Diabetes. Why Consider Insulin Early?
Principles on Treatments & Type 2 Diabetes Jessica Castle, MD Assistant Professor, OHSU Harold Schnitzer Diabetes Health Center Natural History of Type 2 Diabetes Severity of Diabetes UKPDS: Over Time,
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationTiming of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS
Timing of insulin bolus in patients with type 1 diabetes: effect on glucose control and variability using CGMS Idit F Liberty MD, Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel Aviv
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationAdocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationMixing Insulin Glargine With Rapid-Acting Insulin: A Review of the Literature
Feature Article / Mixing Glargine and Rapid-Acting Insulin Mixing Insulin Glargine With Rapid-Acting Insulin: A Review of the Literature Dana G. Carroll, PharmD, BCPS, CDE, and Lisa Meade, PharmD, CDE
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationEveryday Practice: Diabetes Mellitus
THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India
More informationFifty years of diabetes management in primary care
Fifty years of management in primary care MIKE KIRBY Abstract The incidence of has increased exponentially over the last 50 years, meaning that the management of solely by specialist healthcare professionals
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationShort-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00934.x Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis E. Mannucci, M. Monami and N. Marchionni Department of
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationINSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES
INSULIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES Young Jun Rhie, M.D. Department of Pediatrics Korea University Ansan Hospital Introduction 1 Children and adolescents with type 1 diabetes
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationtips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:
tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationInsulin detemir in the treatment of type 1 and type 2 diabetes
AUTHOR COPY REVIEW Insulin detemir in the treatment of type 1 and type 2 diabetes Jean-Christophe Philips André Scheen Division of Diabetes, Nutrition & Metabolic Disorders, Department of Medicine, CHU
More informationInsulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationSelf-Monitoring Of Blood Glucose (SMBG)
Self-Monitoring Of Blood Glucose (SMBG) Aim(s) and objective(s) It is important is to ensure that people with Diabetes are given the opportunity to self monitor their blood glucose appropriately as an
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationInsulin detemir versus insulin glargine for type 2 diabetes mellitus (Review)
Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review) Swinnen SG, Simon ACR, Holleman F, Hoekstra JB, DeVries JH This is a reprint of a Cochrane review, prepared and maintained
More informationSolomon S. Steiner, Lutz Heinemann, Roderike Pohl, Frank Flacke, Andreas Pfützner, Patrick V. Simms, Marcus Hompesch. EASD September 18, 2007
Pharmacokinetics and Pharmacodynamics of Insulin VIAject TM, Insulin Lispro and Regular Human Insulin When Injected Subcutaneously Immediately Before a Meal in Patients with Type 1 Diabetes. Solomon S.
More informationSafety and Effectiveness of Modern Insulin Therapy: The Value of Insulin Analogs
STEPHEN BRUNTON, MD Cabarrus Family Medicine Residency Program, Charlotte, NC Safety and Effectiveness of Modern Insulin Therapy: Dr Brunton is director of faculty development at the Cabarrus Family Medicine
More informationClinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes.
PROTOCOL Clinical and cost-effectiveness of continuous subcutaneous insulin infusion therapy in diabetes. A. This the revised protocol (April 2002) B. Review team Contact for correspondence: Dr Jill Colquitt
More informationMany patients with type 2 diabetes will ultimately need
SUPPLEMENT TO JAPI april 2011 VOL. 59 17 Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of
More informationEvolution of Insulin Development: Focus on Key Parameters
Adv Ther (2012) 29(7):590 619. DOI 10.1007/s12325-012-0034-8 REVIEW Evolution of Insulin Development: Focus on Key Parameters Joseph M. Tibaldi To view enhanced content go to www.advancesintherapy.com
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationShanmugasundar G., Anil Bhansali, Rama Walia, Pinaki Dutta & Vimal Upreti
Indian J Med Res 135, January 2012, pp 78-83 Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus A
More informationTypes of Diabetes
Anti-Diabetic Drugs Bassim I Mohammad Specialist Physician-Assistant Professor College of Pharmacy/ Al Qadisiyah University Iraq Diabetes Mellitus (Definition) DM is an elevated blood glucose level associated
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationJK SCIENCE. Newer Insulins. Jasleen Kaur, Dinesh K. Badyal
REVIEW ARTICLE Introduction Diabetes is rapidly reaching epidemic proportions, affecting 174 million people worldwide and this number is likely to double by year 2030 (1). Insulins are the mainstay of
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationInsulin glulisine (GLU) is a rapid-acting insulin analog. Original Article
DIABETES TECHNOLOGY & THERAPEUTICS Volume 13, Number 6, 2011 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2010.0224 Original Article Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationInpatient Treatment of Diabetes
Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationLipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series
Lipodystrophy: Metabolic and Clinical Aspects Resource Room Slide Series Current Thinking About the Diagnosis and Treatment of the Insulin-Resistant State: How to Use Insulin Therapy Irl B. Hirsch, MD
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationOptimizing Insulin Therapy. Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors
Optimizing Insulin Therapy Calculating Insulin to Carbohydrate Ratios and Correction/Sensitivity Factors Introduction Diabetes management, and particularly self-management, has come a long way. Unfortunately,
More informationInsulin Lispro - A Review
Introduction Insulin Lispro - A Review Pages with reference to book, From 212 To 214 Zarina Muzaffer ( Pakistan Institute of Medical Sciences, Islamabad. ) Ahmar lqbal ( Eli Lilli Pakistan (Private) Limited,
More informationInsulin Therapy for Optimizing Glycemic Control in Type 2 DM. Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013
Insulin Therapy for Optimizing Glycemic Control in Type 2 DM Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013 Case 1 A 45 years-old Thai female with T2DM for 3 years
More information